Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MLTX
MLTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MLTX News
Trump Rejects Iran's Revised Proposal Amid Geopolitical Tensions
1d ago
stocktwits
U.S. Stock Futures Decline as Oil Prices Exceed $100 Again
1d ago
stocktwits
MoonLake Receives FDA Approval for Drug Label Update
1d ago
stocktwits
MoonLake Achieves Positive Consensus with FDA on BLA Submission for Sonelokimab
1d ago
Newsfilter
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
Apr 18 2026
Fool
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
Apr 18 2026
NASDAQ.COM
BVF Partners Sells $62.96 Million in MoonLake Immunotherapeutics Shares
Apr 07 2026
Fool
BVF Sells 3.75 Million Shares of MoonLake Immunotherapeutics
Apr 07 2026
NASDAQ.COM
MoonLake's Clinical Trial Results Spark Interest
Mar 31 2026
stocktwits
MoonLake Immunotherapeutics Phase 3 Trial Results Show Promising Outcomes
Mar 30 2026
NASDAQ.COM
Escalating Middle East Tensions Impact Markets
Mar 30 2026
stocktwits
MLTX Stock Soars After Positive Phase 3 Results for Lead Skin Disease Treatment, Most Patients Show Improvement
Mar 30 2026
stocktwits
Rothschild & Co Upgrades MoonLake to Buy on Approval Path Clarity
Mar 19 2026
seekingalpha
Cormorant Asset Management Increases Stake in MoonLake Immunotherapeutics
Mar 17 2026
Fool
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
MoonLake Immunotherapeutics Receives Upgraded Rating
Feb 23 2026
Yahoo Finance
Show More News
